

Daniel P Morin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7007239/publications.pdf>

Version: 2024-02-01

84
papers

1,816
citations

304743

22
h-index

276875

41
g-index

94
all docs

94
docs citations

94
times ranked

2804
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantification of Resting Myocardial Blood Flow Using Rubidium ⁸² ; Positron Emission Tomography in Regions with MRI-Confirmed Myocardial Scar. <i>Annals of Nuclear Cardiology</i> , 2022, 8, 7-13.	0.2	1
2	The ENHANCE-AF clinical trial to evaluate an atrial fibrillation shared decision-making pathway: Rationale and study design. <i>American Heart Journal</i> , 2022, 247, 68-75.	2.7	4
3	Google Search Activity and Heart Failure: Analysis of the US Population's Interest in Heart Failure and Its Correlation with Heart Failure-Associated Mortality. <i>Journal of Cardiac Failure</i> , 2021, 27, 123-125.	1.7	1
4	PET Stress Testing with Coronary Flow Capacity in the Evaluation of Patients with Coronary Artery Disease and Left Ventricular Dysfunction: Rethinking the Current Paradigm. <i>Current Cardiology Reports</i> , 2021, 23, 50.	2.9	0
5	The role of atrial fibrillation catheter ablation in patients with heart failure. <i>Progress in Cardiovascular Diseases</i> , 2021, 66, 80-85.	3.1	1
6	Leadless and Wireless Cardiac Devices: The Next Frontier in Remote Patient Monitoring. <i>Current Problems in Cardiology</i> , 2021, 46, 100800.	2.4	7
7	Epidemiology, evaluation, and management of conduction disturbances after transcatheter aortic valve replacement. <i>Progress in Cardiovascular Diseases</i> , 2021, 66, 37-45.	3.1	6
8	Right ventricular lead location and outcomes among patients with cardiac resynchronization therapy: A meta-analysis. <i>Progress in Cardiovascular Diseases</i> , 2021, 66, 53-60.	3.1	2
9	Blood Thinners for Atrial Fibrillation Stroke Prevention. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009389.	4.8	2
10	Critical role of cardiac magnetic resonance in the diagnosis of left-dominant arrhythmogenic cardiomyopathy: A paradigmatic case in a recreational middle-aged athlete. <i>HeartRhythm Case Reports</i> , 2021, 7, 453-456.	0.4	1
11	Diagnosis of pulmonary embolism: Know your strengths well, and know your weaknesses better. <i>Trends in Cardiovascular Medicine</i> , 2021, , .	4.9	0
12	Development and validation of a multivariable risk prediction model for COVID-19 mortality in the Southern United States. <i>Mayo Clinic Proceedings</i> , 2021, 96, 3030-3041.	3.0	2
13	Impact of Preinfection Left Ventricular Ejection Fraction on Outcomes in COVID-19 Infection. <i>Current Problems in Cardiology</i> , 2021, 46, 100845.	2.4	5
14	Cancer Radiation Therapy May Be Associated With Atrial Fibrillation. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 610915.	2.4	21
15	First in human: the effects of biventricular pacing on cardiac output in severe pulmonary arterial hypertension. <i>Heart and Vessels</i> , 2020, 35, 852-858.	1.2	1
16	In reply: Impaired myocardial blood flow in atrial fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 1883-1883.	1.7	1
17	Utility of serial measurement of biomarkers of cardiovascular stress and inflammation in systolic dysfunction. <i>Europace</i> , 2020, 22, 1044-1053.	1.7	0
18	Positron emission tomography absolute stress myocardial blood flow for risk stratification in nonischemic cardiomyopathy. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 1137-1146.	1.7	0

#	ARTICLE	IF	CITATIONS
19	Impact of wearable cardioverter-defibrillator compliance on outcomes in the VEST trial: As-treated and per-protocol analyses. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 1009-1018.	1.7	52
20	Class 1C antiarrhythmic drugs in atrial fibrillation and coronary artery disease. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 607-611.	1.7	13
21	Advances in the Risk Stratification, Prevention, and Treatment of Sudden Cardiac Death. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 203-204.	3.1	3
22	Who Should Receive a Wearable Defibrillator Vest at Hospital Discharge?. <i>Current Cardiology Reports</i> , 2019, 21, 125.	2.9	0
23	In reply "Atrial Fibrillation and Morbidity and Mortality in Stress-Induced Cardiomyopathy. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2148-2149.	3.0	0
24	The wearable cardioverter-defibrillator vest: Indications and ongoing questions. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 256-264.	3.1	3
25	Sudden cardiac death in Long QT syndrome (LQTS), Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia (CPVT). <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 227-234.	3.1	40
26	Sudden cardiac death in nonischemic cardiomyopathy. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 235-241.	3.1	13
27	Non-arrhythmic causes of sudden death: A comprehensive review. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 265-271.	3.1	5
28	Direct His bundle pacing using retrograde mapping in complete heart block and L-transposition of the great arteries. <i>Heart Rhythm Case Reports</i> , 2019, 5, 291-293.	0.4	5
29	The impact of revascularization on myocardial blood flow as assessed by positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1226-1239.	6.4	26
30	Editorial commentary: The Checklist Manifesto: Cardiogenic Shock Edition. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 418-419.	4.9	0
31	Management of Perioperative Anticoagulation for Device Implantation. <i>Cardiac Electrophysiology Clinics</i> , 2018, 10, 99-109.	1.7	6
32	To the Editor "Disseminated intravascular coagulation as a cause of shock related to device extraction. <i>Heart Rhythm</i> , 2018, 15, e35.	0.7	0
33	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?. <i>Europace</i> , 2018, 20, 1399-1421.	1.7	75
34	Optimal method of measuring the T-peak to T-end interval for risk stratification in primary prevention. <i>Europace</i> , 2018, 20, 698-705.	1.7	30
35	Current Evidence-Based Understanding of the Epidemiology, Prevention, and Treatment of Atrial Fibrillation. <i>Current Problems in Cardiology</i> , 2018, 43, 241-283.	2.4	14
36	Pacemaker failure as a cause of sudden death. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 293-293.	2.8	0

#	ARTICLE	IF	CITATIONS
37	Editorial commentary: Arrhythmias in patients with left ventricular assist devices: Pump fixed; rhythm â€¦ not so much. Trends in Cardiovascular Medicine, 2018, 28, 51-52.	4.9	0
38	Wearable Cardioverterâ€“Defibrillator after Myocardial Infarction. New England Journal of Medicine, 2018, 379, 1205-1215.	27.0	229
39	Cost-Saving Opportunities with Appropriate Utilization of Cardiac Telemetry. American Journal of Cardiology, 2018, 122, 1570-1573.	1.6	6
40	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?. Journal of Arrhythmia, 2018, 34, 99-123.	1.2	41
41	HRS publications' online development. Heart Rhythm, 2018, 15, 797.	0.7	0
42	Implantable Cardioverter-defibrillators in Adult Congenital Heart Disease. Journal of Innovations in Cardiac Rhythm Management, 2018, 9, 3172-3181.	0.5	1
43	The effect of coronary revascularization on regional myocardial blood flow as assessed by stress positron emission tomography. Journal of Nuclear Cardiology, 2017, 24, 961-974.	2.1	16
44	In Replyâ€“Atrial Fibrillation: Interatrial Block May Be an Underdiagnosed and Easily Recognizable Risk Factor. Mayo Clinic Proceedings, 2017, 92, 682.	3.0	0
45	Extreme â€œcannon A wavesâ€•and pulsatile skin color in complete heart block. HeartRhythm Case Reports, 2017, 3, 493.	0.4	0
46	Prediction and Prevention of Sudden Cardiac Death. Cardiac Electrophysiology Clinics, 2017, 9, 631-638.	1.7	26
47	Device-detected subclinical atrial tachyarrhythmias: definition, implications and managementâ€“an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci3n CardAaca y ElectrofisiologAa (SOLEACE). Europace, 2017, 19, 1556-1578.	1.7	186
48	Evaluating the benefits of home-based management of atrial fibrillation: current perspectives. Journal of Pragmatic and Observational Research, 2016, Volume 7, 41-53.	1.5	0
49	Effects of hydrothermal carbonization conditions on the textural and electrical properties of activated carbons. Carbon, 2016, 107, 619-621.	10.3	13
50	Tailored activated carbons for supercapacitors derived from hydrothermally carbonized sugars by chemical activation. RSC Advances, 2016, 6, 110629-110641.	3.6	17
51	The State of the Art. Mayo Clinic Proceedings, 2016, 91, 1778-1810.	3.0	154
52	The Many Faces of Sudden Death. Mayo Clinic Proceedings, 2016, 91, 1489-1492.	3.0	1
53	Predicting Persistent Left Ventricular Dysfunction Following Myocardial Infarction. Journal of the American College of Cardiology, 2016, 67, 1186-1196.	2.8	68
54	Editorial commentary: MADITâ€“CRT and his many sons. Trends in Cardiovascular Medicine, 2016, 26, 147-149.	4.9	2

#	ARTICLE	IF	CITATIONS
55	From the Editor's Desk: Ochsner Journal Focus Issue: Cardiovascular Diseases. Ochsner Journal, 2016, 16, 193.	1.1	0
56	Surface Electrocardiogram Predictors of Sudden Cardiac Arrest. Ochsner Journal, 2016, 16, 280-9.	1.1	26
57	Natural History and Implantable Cardioverter-Defibrillator Implantation After Revascularization for Stable Coronary Artery Disease With Depressed Ejection Fraction. Clinical Cardiology, 2015, 38, 715-719.	1.8	4
58	Bitumen Shear Mechanics in a Dynamic Subsea Electrical Cable. , 2015, , .		2
59	Laser-assisted extraction of a pacing lead with a supraclavicular course. HeartRhythm Case Reports, 2015, 1, 120-122.	0.4	0
60	T-peak to T-end interval for prediction of ventricular tachyarrhythmia and mortality in a primary prevention population with systolic cardiomyopathy. Heart Rhythm, 2015, 12, 1789-1797.	0.7	54
61	Advances in the Prevention and Treatment of Atrial Fibrillation. Progress in Cardiovascular Diseases, 2015, 58, 103-104.	3.1	5
62	Atrial Fibrillation and Heart Failure: Update 2015. Progress in Cardiovascular Diseases, 2015, 58, 126-135.	3.1	50
63	Lifestyle Modification in the Prevention and Treatment of Atrial Fibrillation. Progress in Cardiovascular Diseases, 2015, 58, 117-125.	3.1	47
64	A little Red Bull may give you wings, but it probably will not affect your Tpe. Anatolian Journal of Cardiology, 2015, 15, 923-924.	0.9	0
65	An Uncommon Cause of Pacemakerâ€Mediated Ventricular Tachycardia. Journal of Cardiovascular Electrophysiology, 2014, 25, 107-109.	1.7	4
66	Atrial Fibrillation and Congestive Heart Failure. Heart Failure Clinics, 2014, 10, 305-318.	2.1	19
67	Cardiac resynchronization therapy: history, present status, and future directions. Ochsner Journal, 2014, 14, 596-607.	1.1	26
68	Correction to "Cardiometabolic Risk Factors and Atrial Fibrillation" [Rev Cardiovasc Med. 2013;14(2-4):e73-e81]. Reviews in Cardiovascular Medicine, 2014, 15, 74-74.	1.4	0
69	Atrial Fibrillation in the 21st Century: A Current Understanding of Risk Factors and Primary Prevention Strategies. Mayo Clinic Proceedings, 2013, 88, 394-409.	3.0	125
70	Cardiometabolic risk factors and atrial fibrillation. Reviews in Cardiovascular Medicine, 2013, 14, e73-81.	1.4	12
71	Cardiometabolic Risk Factors and Atrial Fibrillation. Reviews in Cardiovascular Medicine, 2013, 14, 73-81.	1.4	16
72	Relationships between the T-peak to T-end interval, ventricular tachyarrhythmia, and death in left ventricular systolic dysfunction. Europace, 2012, 14, 1172-1179.	1.7	61

#	ARTICLE	IF	CITATIONS
73	Computed tomography of a coronary sinus diverticulum associated with Wolff-Parkinson-White syndrome. <i>Heart Rhythm</i> , 2012, 9, 1338-1339.	0.7	9
74	Reply to Madias et al. Is the Different Frequency of T-Wave Inversion in Arrhythmogenic Right Ventricular Cardiomyopathy and Idiopathic Ventricular Tachycardia Due to Different Frequency and Duration of Ventricular Ectopy Inducing a Different Degree of Cardiac Memory Effect? <i>Am J Cardiol</i> 2010;106:1522. <i>American Journal of Cardiology</i> , 2011, 107, 144.	1.6	0
75	Progression from Concentric Left Ventricular Hypertrophy and Normal Ejection Fraction to Left Ventricular Dysfunction. <i>American Journal of Cardiology</i> , 2011, 108, 992-996.	1.6	45
76	Iatrogenic Twiddler's Syndrome. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2010, 29, 135-137.	1.3	2
77	Usefulness of Precordial T-Wave Inversion to Distinguish Arrhythmogenic Right Ventricular Cardiomyopathy from Idiopathic Ventricular Tachycardia Arising from the Right Ventricular Outflow Tract. <i>American Journal of Cardiology</i> , 2010, 105, 1821-1824.	1.6	34
78	QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study. <i>European Heart Journal</i> , 2009, 30, 2908-2914.	2.2	59
79	Effect of oral β -blocker therapy on microvolt T-wave alternans and electrophysiology testing in patients with ischemic cardiomyopathy. <i>American Heart Journal</i> , 2007, 153, 392-397.	2.7	21
80	Effect of bundle branch block on microvolt T-wave alternans and electrophysiologic testing in patients with ischemic cardiomyopathy. <i>Heart Rhythm</i> , 2007, 4, 904-912.	0.7	27
81	Predictive Value of Microvolt T-Wave Alternans in Patients With Left Ventricular Dysfunction. <i>Journal of the American College of Cardiology</i> , 2007, 50, 166-173.	2.8	60
82	Management of ventricular tachycardia in the absence of structural heart disease. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2007, 9, 356-363.	0.9	2
83	Selective Estrogen-Receptor Modulators. <i>New England Journal of Medicine</i> , 2003, 348, 2259-2259.	27.0	3
84	Is the Match Illegal?. <i>New England Journal of Medicine</i> , 2003, 348, 2259-2262.	27.0	0